<DOC>
	<DOCNO>NCT02670785</DOCNO>
	<brief_summary>This study access safety efficacy three dos estradiol vaginal capsule postmenopausal woman vulvovaginal atrophy .</brief_summary>
	<brief_title>A Safety Efficacy Study Estradiol Vaginal Capsule Postmenopausal Women With Vulvovaginal Atrophy</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Dyspareunia</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Clinical diagnosis vulvovaginal atrophy due post menopause Age ≥ 40 year bilateral oophorectomy ≥ 35 year Moderate severe vaginal dryness Normal breast exam ; &gt; 40 year Vaginal pH &gt; 5.0 &lt; 5 % superficial cell vaginal wall cytology smear Known hypersensitivity estrogen and/or progestin therapy Known suspect premalignant malignant disease Undiagnosed abnormal genital bleed A history treatment significant cardiovascular disease , congestive heart failure , stroke Active know protein C , protein S , antithrombin deficient , know thrombophilic disorder thromboembolic event Increased frequency/severity headache estrogen therapy Smokes ≥ 15 cigarettes/day</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>